PURE Bioscience Reports Fiscal Year End 2014 Financial Results
Marketwired - Tue Oct 28, 3:03PM CDT
PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal year ended July 31, 2014 (Fiscal 2014).
PURE Bioscience Names Tom Y. Lee, CPA, as Sixth Member of Its Board of Directors
Marketwired - Mon Oct 27, 7:36AM CDT
PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced the appointment of Tom Y. Lee, CPA, to its Board of Directors. Lee will also serve on the Company's Audit Committee.
PURE Bioscience Hosts Year-End Results Conference Call October 28, 2014 to Review Progress of SDC Antimicrobial-Based Food Safety Solutions Strategy
Marketwired - Mon Oct 20, 7:36AM CDT
PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced that the Company will host an investor conference call on Tuesday, October 28, 2014 at 1:30pm PDT (4:30pm EDT).
PURE Hard Surface Disinfectant Now Available for Use in Subway(R) Restaurants Nationwide
Marketwired - Fri Oct 17, 7:32AM CDT
PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, announced today that PURE Hard Surface disinfectant has been made available for use in the almost 27,000 SUBWAY(R) franchised locations in the U.S.
PURE Submits Food Contact Notification to FDA for SDC Antimicrobial Use in Produce Processing
Marketwired - Thu Oct 09, 7:36AM CDT
PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced that it has submitted a Food Contact Notification (FCN) to the U.S. Food and Drug Administration (FDA) for Silver Dihydrogen Citrate (SDC) as a produce processing aid, expanding the use for SDC as a direct food contact substance. Test results demonstrate significant log reductions in Salmonella, Listeria and E. coli O157:H7 when applied to leafy greens.
PURE Bioscience to Present at Rodman & Renshaw Annual Global Investment Conference
Marketwire - Thu Aug 21, 7:36AM CDT
PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced that Hank R. Lambert, CEO, will present at the Rodman & Renshaw Annual Global Investment Conference sponsored by H.C. Wainwright & Co., LLC., on Wednesday, September 10th, at 1:40pm EDT, at the New York Palace Hotel.
PURE Bioscience out-licenses non-food-safety-related SDC products to Research Instruments for the IVF Market
M2 - Wed Aug 20, 4:15AM CDT
SDC antimicrobial company PURE Bioscience (OTCQB
PURE Bioscience Licenses SDC Antimicrobial for Medical Device Disinfectant Use in IVF Market
Marketwire - Tue Aug 19, 7:46AM CDT
PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced that, as part of its strategy to out-license non-food-safety-related markets for SDC, it has entered into a license and distribution agreement with UK-based Research Instruments Limited. The agreement provides for the limited exclusive, worldwide use of an SDC-based surface disinfectant in the niche field of human and animal in-vitro fertilization where SDC, subject to appropriate regulatory approval as a medical device, will be used to disinfect other non-invasive medical devices and instruments used in assisted reproduction facilities.
PURE Submits Food Contact Notification to FDA for SDC Antimicrobial Use in Raw Poultry Processing
Marketwire - Mon Jul 14, 7:35AM CDT
PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced that it has submitted a Food Contact Notification (FCN) to the U.S. Food and Drug Administration (FDA) for Silver Dihydrogen Citrate (SDC) as an online reprocessing (OLR) antimicrobial for raw poultry processing. Previously reported test results demonstrated materially significant reduction in Salmonella contamination in poultry.
PURE Bioscience Reports Fiscal Second Quarter 2014 Financial Results
Marketwire - Thu Mar 13, 3:02PM CDT
PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the second fiscal quarter ended January 31, 2014.
PURE Bioscience Hosts Q2 Results Conference Call March 13th, 2014 and Reviews Progress of SDC-Based Food Safety Solutions Strategy
Marketwire - Mon Mar 03, 7:30AM CST
PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced that the Company will host an investor conference call on Thursday, March 13th, 2014 at 1:30pm PDT (4:30pm EDT).
PURE's SDC-Based Food Safety Solutions Strategy Gains Traction -- Initial Orders From Three Food Processors
Marketwire - Thu Jan 16, 7:30AM CST
PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced continued progress on its strategic positioning as a food safety solution which was launched this past Fall.
5W Public Relations Expands Corporate Practice, Adds PURE Bioscience, Inc. to Client Roster
PR Newswire - Wed Dec 18, 7:45AM CST
5W Public Relations, one of the 25 largest independent public relations firms in the U.S., announced the addition of PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial agent, to its diverse roster of corporate clients.
ELON: 1.97 (+0.01)
PURE Bioscience Appoints New CEO
Marketwire - Tue Sep 10, 7:30AM CDT
PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced the appointment of Hank Lambert as its new Chief Executive Officer. Mr. Lambert replaces the interim CEO, Dave Pfanzelter, who remains as Chairman of the Board. The company reported that the management change is part of its previously announced reorganization establishing new and experienced leadership focused on commercialization of SDC technology in the food industry as a unique and proprietary antimicrobial agent to protect consumer safety against various pathogens.
PURE Bioscience expands sales and marketing team with addition of Cliff Wechsler & Tom Myers
M2 - Thu Aug 29, 4:35AM CDT
Antimicrobial company PURE Bioscience (OTCQB
PURE Bioscience Strengthens Sales and Marketing Organization
Marketwire - Wed Aug 28, 7:30AM CDT
PURE Bioscience (OTCQB: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced the strengthening of its sales and marketing leadership team. The company appointed Cliff Wechsler as its new Executive Vice President of Sales, and Tom Myers assumed the position of Executive Vice President of Marketing and Product Development. The company reported that the management change established the leadership to drive the commercialization of SDC technology in the food industry as a novel and proprietary antimicrobial agent to protect consumer safety against various pathogens.
Delisting of Securities of SmartHeat Inc., Ampal-American Israel Corporation, PURE Bioscience, Inc., Urologix, Inc. and Strategic Diagnostics Inc. From The NASDAQ Stock Market
GlobeNewswire - Mon Aug 19, 3:05PM CDT
The NASDAQ Stock Market announced today that it will delist the common stock of SmartHeat Inc. SmartHeat Inc.'s stock was suspended on November 09, 2012 and has not traded on NASDAQ since that time.
NDAQ: 41.82 (+0.83)
OTC Daily Alert Stock Watch - PURE Bioscience, Inc. (OTCQB: PURE)
WorldStockWire - Sat Aug 17, 5:15PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
PURE Bioscience Appoints New Board Members and Management Team
Marketwire - Tue Aug 13, 4:00PM CDT
PURE Bioscience (OTCQB: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced a leadership reorganization beginning with the return of Dave Pfanzelter as chairman of the board of directors. Mr. Pfanzelter will also serve as interim chief executive officer while the company initiates the process of recruiting a new CEO. The company's former chief financial officer, Peter C. Wulff, also agreed to return to the company to serve as both its CFO and chief operating officer. In addition, the company has appointed Gary Cohee to the board of directors.
PURE Bioscience Inc's net loss narrows to USD1.5m in Q3 fiscal 2013
M2 - Mon Jun 17, 4:23AM CDT
Antimicrobial company PURE Bioscience Inc (OTCQB